Form 4: Inari Medical Director William Hoffman Sells Shares Under 10b5-1 Plan

Director William Hoffman of Inari Medical sold a total of 200,000 shares of common stock on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• William Hoffman, a director at Inari Medical, sold 141,075 shares of common stock at a weighted average price of $60.13 per share on January 6, 2025.
• He also sold 58,925 shares of common stock at a weighted average price of $61.27 per share on the same day.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these sales, Hoffman directly owns 238,987 shares of Inari Medical common stock.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider stock sales under a pre-arranged plan, which is neither positive nor negative in itself. It is a neutral event.

Risks

• Large sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate insiders at publicly traded companies, including those in the medical device industry like Inari Medical.
• Similar filings are regularly seen from directors and officers at companies like Boston Scientific, Medtronic, and Abbott, when they execute trades under pre-arranged plans.

Stakeholder Impact

• The stock sales could potentially have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Inari Medical, William Hoffman, insider trading, stock sale, Form 4, Rule 10b5-1, NARI